問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Endocrinology

Division of Neurology

Cheng Hsin General Hospital (在職)

Division of Neurology

更新時間：2023-09-19

蔡清標
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡清標

List

8Cases

2020-09-01 - 2024-03-08

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2013-04-01 - 2019-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2013-11-01 - 2014-10-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2011-10-01 - 2012-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-03-01 - 2010-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2009-01-01 - 2014-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2016-11-16 - 2020-01-31

Phase III

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of SA237 as monotherapy in patients with neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD).

  • Condition/Disease

    neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD)

  • Test Drug

    SA237

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

郭育呈
China Medical University Hospital

Division of Neurology

2014-02-01 - 2021-12-31

Phase III

A MULTICENTER, RANDOMIZED, ADDITION TO BASELINE TREATMENT, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SA237 IN PATIENTS WITH NEUROMYELITIS OPTICA (NMO) AND NMO SPECTRUM DISORDER (NMOSD)

  • Condition/Disease

    NEUROMYELITIS OPTICA (NMO) AND NMO SPECTRUM DISORDER (NMOSD)

  • Test Drug

    SA237

Participate Sites
5Sites

Terminated5Sites

郭育呈
China Medical University Hospital

Division of Neurology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB